185 related articles for article (PubMed ID: 33331880)
1. Assessment and Simplification of Treatment Eligibility Among Patients With Chronic Hepatitis B Infection in Vietnam.
Vu Hai V; Shimakawa Y; Kim J; Do Ngoc H; Le Minh Q; Laureillard D; Lemoine M
Clin Infect Dis; 2021 Sep; 73(5):e1072-e1077. PubMed ID: 33331880
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa.
Shimakawa Y; Ndow G; Njie R; Njai HF; Takahashi K; Akbar SMF; Cohen D; Nayagam S; Jeng A; Ceesay A; Sanneh B; Baldeh I; Imaizumi M; Moriyama K; Aoyagi K; D'Alessandro U; Mishiro S; Chemin I; Mendy M; Thursz MR; Lemoine M
Clin Infect Dis; 2020 Mar; 70(7):1442-1452. PubMed ID: 31102406
[TBL] [Abstract][Full Text] [Related]
3. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.
Shimakawa Y; Njie R; Ndow G; Vray M; Mbaye PS; Bonnard P; Sombié R; Nana J; Leroy V; Bottero J; Ingiliz P; Post G; Sanneh B; Baldeh I; Suso P; Ceesay A; Jeng A; Njai HF; Nayagam S; D'Alessandro U; Chemin I; Mendy M; Thursz M; Lemoine M
J Hepatol; 2018 Oct; 69(4):776-784. PubMed ID: 30104154
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
5. Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia.
Vinikoor MJ; Sinkala E; Kanunga A; Muchimba M; Zanolini A; Saag M; Pry J; Nsokolo B; Chisenga T; Kelly P
PLoS One; 2020; 15(1):e0227041. PubMed ID: 31929556
[TBL] [Abstract][Full Text] [Related]
6. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.
Minier N; Guingané AN; Okeke E; Sinkala E; Johannessen A; Andersson MI; Davwar P; Desalegn H; Duguru M; Fall F; Mboup S; Maponga T; Matthews PC; Ramírez Mena A; Ndow G; Orlien SMS; Riches N; Seydi M; Sonderup M; Spearman CW; Stockdale AJ; Taljaard J; Vinikoor M; Wandeler G; Lemoine M; Shimakawa Y; Sombié R
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):323-332. PubMed ID: 38367633
[TBL] [Abstract][Full Text] [Related]
8. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
9. A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B.
Geeratragool T; Tangkijvanich P; Nimanong S; Chainuvati S; Charatcharoenwitthaya P; Tanwandee T; Chotiyaputta W
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992433
[No Abstract] [Full Text] [Related]
10. Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B.
Post G; Howell J; Sow A; Ndow G; Chemin I; Lo G; Cessay A; Cohen D; Njie R; Toure S; Diop M; Sombie R; Nana J; Leroy V; Lacombe K; Bojang L; Tacke F; Toure-Kane C; Ka M; Mendy M; Mboup S; Thursz M; Shimakawa Y; Ingiliz P; Lemoine M
J Viral Hepat; 2021 Jul; 28(7):1003-1010. PubMed ID: 33749097
[TBL] [Abstract][Full Text] [Related]
11. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
12. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.
Oliveri F; Coco B; Ciccorossi P; Colombatto P; Romagnoli V; Cherubini B; Bonino F; Brunetto MR
World J Gastroenterol; 2008 Oct; 14(40):6154-62. PubMed ID: 18985805
[TBL] [Abstract][Full Text] [Related]
13. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
[No Abstract] [Full Text] [Related]
15. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
Jeng WJ; Sheen IS; Chen YC; Hsu CW; Chien RN; Chu CM; Liaw YF
Hepatology; 2013 Dec; 58(6):1888-96. PubMed ID: 23744454
[TBL] [Abstract][Full Text] [Related]
16. Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection.
Post G; Shalev N; Baumgarten A; Shimakawa Y; Lemoine M; Krznaric I; Dupke S; Carganico A; Arastéh K; Ingiliz P
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):723-728. PubMed ID: 30964812
[TBL] [Abstract][Full Text] [Related]
17. Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
Wong RJ; Kaufman HW; Niles JK; Kapoor H; Gish RG
Clin Infect Dis; 2023 Feb; 76(3):e791-e800. PubMed ID: 35594550
[TBL] [Abstract][Full Text] [Related]
18. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
19. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT.
Wu Z; Ma AL; Xie Q; Zhang XQ; Cheng J; Zhang DZ; Wang GQ; Zhao H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101463. PubMed ID: 32571749
[TBL] [Abstract][Full Text] [Related]
20. Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B.
Kim SB; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
J Gastroenterol Hepatol; 2016 Jan; 31(1):241-7. PubMed ID: 26204913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
